Literature DB >> 18377809

Pharmacokinetic/Pharmacodynamic antimicrobial individualization and optimization strategies.

Tze-Peng Lim1, Kevin W Garey, Vincent H Tam.   

Abstract

Effective antimicrobial chemotherapy integrates pharmacology and microbiology to achieve the most favorable clinical and microbiologic outcomes. Understanding such relationships allows us to select the optimal drug dose in a rational manner. The difficulty lies in translating the research findings to clinicians at the bedside. Current clinical practices have not embraced fully many advances in pharmacokinetic/pharmacodynamic research. This article summarizes what we have learned over the past decades and highlights some of the barriers to translating these results into clinical practice. Reducing these barriers would help to bring clinically relevant laboratory work to the bedside and would emphasize evidence-based medicine. It may also improve patient outcomes and minimize the emergence of resistance.

Entities:  

Year:  2008        PMID: 18377809     DOI: 10.1007/s11908-008-0004-0

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  24 in total

1.  Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy.

Authors:  Nelson Jumbe; Arnold Louie; Robert Leary; Weiguo Liu; Mark R Deziel; Vincent H Tam; Reetu Bachhawat; Christopher Freeman; James B Kahn; Karen Bush; Michael N Dudley; Michael H Miller; George L Drusano
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

2.  Continuous infusion of vancomycin in methicillin-resistant staphylococcus infection.

Authors:  A Di Filippo; A R De Gaudio; A Novelli; E Paternostro; C Pelagatti; P Livi; G P Novelli
Journal:  Chemotherapy       Date:  1998 Jan-Feb       Impact factor: 2.544

3.  Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection.

Authors:  S L Preston; G L Drusano; A L Berman; C L Fowler; A T Chow; B Dornseif; V Reichl; J Natarajan; F A Wong; M Corrado
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

4.  Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity.

Authors:  M J Rybak; B J Abate; S L Kang; M J Ruffing; S A Lerner; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

5.  Integration of population pharmacokinetics, a pharmacodynamic target, and microbiologic surveillance data to generate a rational empiric dosing strategy for cefepime against Pseudomonas aeruginosa.

Authors:  Vincent H Tam; Arnold Louie; Ben M Lomaestro; George L Drusano
Journal:  Pharmacotherapy       Date:  2003-03       Impact factor: 4.705

6.  Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models.

Authors:  D Andes; W A Craig
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

7.  Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  Pamela A Moise; George Sakoulas; Alan Forrest; Jerome J Schentag
Journal:  Antimicrob Agents Chemother       Date:  2007-04-23       Impact factor: 5.191

8.  Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling.

Authors:  Tawanda Gumbo; Arnold Louie; Mark R Deziel; Linda M Parsons; Max Salfinger; George L Drusano
Journal:  J Infect Dis       Date:  2004-09-24       Impact factor: 5.226

9.  Effectiveness and safety of once-daily aminoglycosides: a meta-analysis.

Authors:  R Ferriols-Lisart; M Alós-Almiñana
Journal:  Am J Health Syst Pharm       Date:  1996-05-15       Impact factor: 2.637

10.  Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients.

Authors:  A Forrest; D E Nix; C H Ballow; T F Goss; M C Birmingham; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.